MENU
+Compare
CANC
ETF ticker: NASDAQ
AS OF
Dec 18, 04:59 PM (EDT)
Price
$24.53
Change
-$1.03 (-4.03%)
Net Assets
44.62M

CANC stock forecast, quote, news & analysis

Category: @Health
CANC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
A.I.Advisor
a Summary for CANC with price predictions
Dec 17, 2024

CANC's Indicator enters downward trend

The Aroon Indicator for CANC entered a downward trend on December 17, 2024. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 39 similar instances where the Aroon Indicator formed such a pattern. In of the 39 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 11, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on CANC as a result. In of 19 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CANC turned negative on December 12, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at .

CANC moved below its 50-day moving average on November 12, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CANC's RSI Indicator exited the oversold zone, of 7 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CANC advanced for three days, in of 83 cases, the price rose further within the following month. The odds of a continued upward trend are .

CANC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL).

Industry description

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Oncology ETF ETF is 25.44B. The market cap for tickers in the group ranges from 3.51M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Oncology ETF ETF was 3%. For the same ETF, the average monthly price growth was 20%, and the average quarterly price growth was 58%. ARGX experienced the highest price growth at 5%, while ARVN experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Tema Oncology ETF ETF was 5%. For the same stocks of the ETF, the average monthly volume growth was -39% and the average quarterly volume growth was -12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 81
Price Growth Rating: 60
SMR Rating: 84
Profit Risk Rating: 76
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
CANC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co